ADC Therapeutics

Quote

anonymous said:
Dear Board:

Now that Ameet and CHS have had over a year to implement their plan lets take a look shall we:
1. Ameet too over with the stock around 10, it is now under 3.
2. KHS wanted to implement her plan with the go to market approach. She cut loose many and many other good reps left. Lets look: No one joining this company has any good options. You have some stay cause they want their title promotion but no one worth a damn joins. Except the several people who have used ADCT to work several jobs at once.
3. Marketing genius Karen has implemented ? Nevermind she is useless too.
You keep creating debt to have a cash balance but no one wants to absord the debt. You are the only ADC company with a drug on the market yet no one is looking to buy.

I can't decide who has created more harm to shareholders managment or the board. You should all take a long look in the mirror and take a personal inventory of your career. You are all leeches!
Click to expand...
Dear Board:

All of the above is still true. Ameet is now working on crafting his message to the 3 new MBA's who will be on the earnings call trying to explain how a drug that has flatlined again at 18 million per quarter is going to be a 500m-1 billion dollar drug. The pipeline is gone and the only thing he does is restructure debt to kick the can down the road, meanwhile the stock is under 2 dollars. Are you overseeing a company or a charity for ex novartis leadership? You have all failed in your oversight duties.
 



Stop your complaining! When Ameet wows em on this earnings call I can see the stock jumping to $1.81 The good times are just around the corner. Keep up the great work Ameet!
Signed all the usual kiss asses
JY, KK, KL, RK and your truly KHS

P.S. Ameet, I dont hold it against you that you cost me the substantial buyout from my last company. I only think about it when I cry myself to sleep.
 



Earnings call transcript:

Hi This is Ameet and I am thrilled to say that earnings rose to 18.1 million for the fourth quarter. We have now had similiar, or stagnate, revenue for the last 10 quarters. The pipeline is a mess and there is no way to generate any capital when the stock is at 1.75. Hold on my recruiter is calling.
 



anonymous said:
Earnings call transcript:

Hi This is Ameet and I am thrilled to say that earnings rose to 18.1 million for the fourth quarter. We have now had similiar, or stagnate, revenue for the last 10 quarters. The pipeline is a mess and there is no way to generate any capital when the stock is at 1.75. Hold on my recruiter is calling.
Click to expand...
Where are the earnings? The one drug has the same revenue every quarter so not sure why everthing is delayed. The Board should hold Ameat and KHS accountable.
 









anonymous said:
Dont say that KHS. I think we can milk this company for at least another 2 years with this poorly run BOD. Just blame the reps like we did with Kymriah. Sincerely Ameat
Click to expand...
Dear BOD:

The 16.4 million in the quarter is the worst number yet since launch. Ameat has driven the share price down about 85% and his go to market sales approach has failed along with his past jobs at NVS and the biotech he drove into the graveyard. Is there anything he can do to have you open your eyes and hold him accountable? Signed every shareholder not named Ameat or KHS. Actaully KHS wants an answer too.
 



Dear BOD:

Help me understand the current shit show. Sales declining and they hire a NSD who happens to be an Ameat and KHS friend. How can you justify the cost with contracting revenue? Also they talk about what is new but nothing is even close to being filed with the FDA. I dont remember seeing the posting for the NSD role so this was clewarly an inside job hire. Maybe you should fire that fat slob in HR too. This place is nothing but a pig trough for NVS catoffs and the BOD will be help liable when the right law firm gets involved.
 




Write your reply...
Top Bottom
Back
Quote